Motley Fool Money - Software Eating The World, Healthcare Stocks to Watch

Episode Date: June 18, 2021

Adobe hits an all-time high on earnings. Kroger raises guidance and announces a $1B stock buyback. The Honest Company issues its first report as a public company. Homebuilder Lennar posts strong profits. And electric-truck maker Lordstown Motors needs new management. Ron Gross and Jason Moser analyze those stories, discuss value plays vs. value traps, weigh in on El Pollo Loco’s flying chickens, and share two stocks on their radar: Qorvo and GAN Limited.  Plus, Motley Fool healthcare contributor Keith Speights discusses the latest on Covid vaccines, Johnson & Johnson, and the controversy surrounding the FDA’s approval of Biogen’s treatment for Alzheimer’s.   Looking for official stock recommendations? Get 50% off Stock Advisor just by going to http://RadarStocks.fool.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

If you're a small business owner, you already know what it takes to keep everything moving. You're juggling customers, invoices, and about 100 decisions every day. Thankfully, taxes don't have to be one more thing on that list. With Intuit TurboTax, you can get your business taxes done for you with a full service expert. TurboTax matches you with your dedicated tax expert. Who knows your industry understands your business write-offs and gives you the personalized advice your business deserves. upload your documents right in the app, hand everything off, and still feel like you're in the loop the whole way through. You can even get real-time updates on your expert's progress right in the app,

which makes it so much easier to stay on track. And you can get unlimited expert help at no extra cost, even on nights and weekends during tax season. Visit turbotax.com to get matched with an expert today, only available with TurboTax full service experts. Everybody needs money. That's why they call it money. From Fool Global Headquarters, this is Motley Fool Money Radio Show. I'm Chris Hill, joining me this week's senior analyst, Jason Moser, and Ron Gross. Good to see you, as always, gentlemen. Hi, Chris. We've got the latest headlines from Wall Street. We've got the latest on the healthcare industry. And as always, we've got a couple of stocks on our radar. But we begin with software eating the world. Shares of Adobe hit a new all-time high on Friday after second quarter profits in revenue came in higher than Wall Street was expecting.

The software company also upped their guidance for the current quarter. Jason, there is a lot to like with Adobe. What stood out to you? Oh, Chris, I am just such a happy shareholder. This was just a lovely quarter, it seems, on all counts. Adobe, it's so interesting. To me, this is one that just hides in plain sight. A lot of people maybe don't own it. They feel like it's too big, or maybe they feel like they're too late. It's not too big and you're not too late. This is one you want to have on your radar.

Ubictuous digital media company utilizing a subscription model, subscription revenue, basically 90% of the business with gross margins to boot. I mean, there are just a lot of good things going on with this business. And when you look at the numbers, I think that really tells the tale for the quarter. I mean, they brought in $3.84 billion in revenue. That was growth of 23% from a year ago. In non-gap earnings per share, $3.3.3. The digital media segment, which is the largest segment of the business, that grew 25% from a year ago. And they exited the quarter, actually, with $11.2 billion of digital media annualized recurring revenue. And so that just gives you a little bit of an idea of what is coming, right? I mean, this is just a company that continues just to keep those partnerships, those relationships,

with his customers because of all of this great software that it produces. One of the more interesting parts of the business, smaller part of the business, but we talk a lot about DocuSign on the show. Adobe has their document cloud. That brought in $470 million in revenue. That was 30% growth from a year ago. New Adobe signed customers doubled from a year ago. So it's clear that they are keeping their customers. They're bringing more customers in, and they're really excited about this recovery in the economy. Adobe's tools are used by so many in so many different spaces. E-commerce is no exception. And they really lobbed out some pretty impressive projections there in regard to e-commerce. They see e-commerce spending.

It's projected to be $4.2 trillion globally this year. I'm going to reach $1 trillion in the U.S. alone in 2022. I mean, that is a really good sign for Adobe because a lot of those customers in e-commerce are using those digital media tools to build and grow their businesses. So, yeah, Like you said, a lot to like. It feels like, you know, if you're a shareholder here, hang on to those shares. Kroger's first quarter profits in revenue came in higher than expected. The grocery chain also raised guidance for the full fiscal year. And despite all that goodness, Ron, shares of Kroger were actually flat this week.

You know, it was a solid report. It was not stellar. The high point, as you point out, was that they increased guidance. But if you just drill down a little bit, some mediocrity there. sales were flat. If you exclude fuel sales, they were actually down 4%. Now, sales were up 14.9% if you compare it to two years ago. And they give us this metrics, as so many other retailers have been, because of COVID. Year over year comparisons are rough this time around. So it's nice to have a more normalized year 2019 to compare to. So it looks pretty good. Sales up almost 15% compared to that. Investments in digital paying off, you know, obviously crucial in this day and age to invest in your digital experience.

Sales there were up 16%. They expanded to over 2,200 pickup locations, almost 2,500 delivery locations, which cover 98% of Kroger households. Gross margins narrowed a bit that's on the weaker sales, higher shrink, shoplifting. Shrink is another word for shoplifting and other losses. And there were some COVID-related expenses in there as well that impacted margins. So, when you boil it all down and you exclude some pension-related charges, adjusted EPS was actually down slightly.

Compared to 2019, again, though, you had an up 29 percent, not too shabby for a supermarket company. And as we said, they raised full-year guidance, which was also nice to see. 2800 retail stores right now, Harris Teeter being my favorite, thank you. Only trading it 13 times. These companies don't typically trade at high multiples, but that's not expensive. and they just approved a new $1 billion share repurchase program. Real quick, the technical term shrink.

Does that include things other than shoplifting? It does. It could be bookkeeping, discrepancies, accounting things. Shoplifting is a big part of it. Other reasons that you would not be able to account for merchandise, falls off the back of a truck, for example. So not just shoplifting. The Honest Company issued its first report as a public company.

The Consumer Goods business founded by actress Jessica Alba posted revenue that was higher than expected, but shares of Honest Company falling this week and down 30 percent from its IPO just last month, Jason. Yeah, I wouldn't worry too much about that. I think this was a very respectable introduction to the public market. A very good first earnings release here. When you look at this business, I mean, it really does. It feels like this is the direction in which the world wants to.

ahead. So, there is a long-term trend in play here that could work out nicely over time, a company that's very focused on ESG and sustainability. I think a big question for a business like this. It really boils down to pricing oftentimes. It's a little bit more expensive to make this stuff right now in the near term. Now, as time goes on, those costs will come down. And I think a company like the honest company has some brand equity that could play out in its favor. They do have to be careful with that, though. But when you look at the numbers, Revenue up 12% from a year ago. They saw a little gross margin pressure there just primarily due to input costs.

And there's some expenses there with additional marketing spend and some IPO costs. But all in all, they view their total addressable market here for their categories of diapers, and wipes and skin and personal care and household products. They see a total market opportunity. They're around $130 billion with about $17 billion, representing that clean and natural market within those categories. And that's really the primary focus of the honest company. So I think, again, a very respectable introduction to the public markets. They should feel good about where they're headed. I think now it's just a matter of making

those sales. And as long as they continue to establish and grow relationships like they're doing with Target, they expanded the presence there, Target from 900 stores to 1,200 stores. Hey, I mean, if you've been listening to this show and you listen to Ron talk about Target, you know that Target's a nice place for these folks to be. Shares of Lanar up more than 7% this week after the home builders' second quarter profits came in higher than expected. Ron, given what's happening to home prices lately, any chance the good people at Lanar could build homes a little more quickly? If it wasn't for some raw material prices and some labor shortages, maybe. But boy,

real estate is on fire all over the place. Strong quarter. Revenue here up 22%. That's due to a 14% increase in deliveries, a 6% increase in average sale price. which, as we say, is a result of the tight supply of homes in the U.S. There is no inventory for homes right now. They had a nice increase in margin in their mortgage business and an increase in volume and margin in their title business. So, that helped results. Gross margin of 26.1 percent was the highest second quarter margin in the company's history. That was driven by a higher than expected sales price per home delivered of $414,000, reflecting higher prices in most markets, as we all see, and that was partially offset by higher land and construction costs. New

orders up 32%. Now, new construction has been constrained due to the pandemic, tight labor market, shortage of lumber. As we saw, lumber prices skyrocket. That's come down a bit recently, but lumber prices very, very high. Other raw materials and commodity prices high as well, as we talk about inflation in so many different industries. But they still put up great numbers, net income, excluding some non-operating charges, and a gain on the The sale of their solar business was up 79 percent, really strong. Guidance was strong for home deliveries and gross margins in the third quarter. They repurchased a million shares of common stock.

Things are going quite well as a result of this real estate market that is on fire. Are we going to have to wait three more months to their next earnings report to get an update on how construction is going? Because it seems like heading into the summer months, one scenario is we get updated guidance from Lanar a month from now. Yeah, that certainly could happen. It's very hard to predict, but we'll have other more macro-related indicators about how construction housing starts, real estate in general, are looking, and we'll be able to

then project into these individual companies. How do you separate a value play from a value trap? We'll discuss that after the break, so stay right here. You're listening to Motley Full Money. Welcome back to Motley Full Money. Chris Hill here with Jason Moser and Ron Gross. Lazy Boy ended the fiscal year with a strong fourth quarter report. Profits and revenue were both solidly higher than Wall Street was expecting, yet shares

of Lazy Boy falling more than 15% this week. What's going on, Ron? Yeah, quarter was fine, benefiting from the economy reopening, but I think it's the outlook primarily that worried investors, and we can get into that as we take you through the quarter. Sales reaching a record high up 41%, so far so good. Obviously, last year, impacted by the pandemic. This year, sales were driven by the reopening of stores.

They had some increased production capacity, strong performance by their company-owned stores. And Joybird, which is their online furniture subsidiary, also had continued growth and was actually profitable. They had same store sales increase of 100%. But if we go back to 2019, as we discussed earlier, they were up only, I say only 29%. That's pretty strong still. So, it's good to see that same star sales number. Sales in the wholesale segment was up 40 percent. Retail segment, 39 percent, very consistent there.

They had operating margins that widened a bit. And adjusted earnings per share were actually up 78 percent. So you say, what's the problem here? Why would the stock sell off? Well, that's when you get into some of the guidance. All business units are experiencing record demand. That's great. Backlog is at record levels.

That is good, but only if you can fill those orders. management expects ongoing global supply chain disruptions, headwinds related to raw materials and fray costs to make filling that backlog somewhat difficult. They expect a temporary negative impact to profit margins due to higher raw material prices. They're going to offset that with some price increases. We see lots of retailers and even restaurant companies doing that as well. So that, I think, is what investors were focused on. I think that's fair because the past is the past. We have to look to the future when we think about our investments. And so perhaps it rightly sold off. This stock is only trading at 12 times. That's fine. It's not some huge

growth company. It's not a technology company. It's a furniture, relatively lower-end furniture retailer. Certainly not an expensive stock, but it's trading probably right around where it should be. Yeah, but Ron, on last week's show, we talked about RH Holdings, parent company of restoration hardware. They're in the same line of work as Lazy Boy. And I'm a lot of the way. And I I don't remember them saying they were facing any of these problems to this degree. RH is doing a stellar job in terms of sourcing, in terms of their galleries, in terms of their loyalty program.

They're obviously a much higher price point as well, which I think has benefited their results. So yeah, two different stories. Exciting week at Lordstown Motors. The electric truck startup is looking for new management because CEO Steve Burns and CFO Julio Rodriguez resigned on the same day. Shares of Lourdes Town down 10%. Jason, I'm kind of surprised. It's not down more than that. Yeah, exciting maybe for the financial media, right? Because we get to talk about this.

I'd imagine if you're an investor in Lourdes Town, excited maybe isn't really the word. Man, it really feels like a lot of unforced errors here. But I think it's also a very good example of the dangers that Spacks can present. I mean, it's not to lump them altogether, any means. There are plenty of great spacks out there that are working out well, but they're by their very nature. They're more story stocks. They come to the market far earlier in their lives as going concerned. So you need to make sure there's some stake behind that sizzle, Chris. And it looks like with Lords Town, there might not be yet at least. And I mean, it was really interesting to see this story develop through the week because on Tuesday, which was a day after

the CEO and the CFO resigned, the president of the company, told reporters that the company had enough cash on hand to get through next May and enough binding orders to keep production going through the end of next year. Well, then fast forward to Thursday where the company files an 8K in order to clarify the president's comments because they're like, hey, listen, what this is, there's some purchase agreements that provide us with some signals of demand, but that they actually have no binding purchase orders or commitments from customers. So, you know, I don't know if it's semantics. I don't know if the president was trying to paint

a little bit of a better picture than is really the case. But the bottom line is that leadership clearly, they're not all on the same page. And when you have a business like this that is essentially pre-revenue and they are facing monumental competition, I mean, not only from a company like Tesla, which is clearly the leader in the EV space, but now you've got GM and Ford making all of these commitments to invest in EVs as well, spending billions upon billions of dollars to do so. It just goes to show you really how big, how steep of an uphill climate really is for Lordsdown. Based on what we've seen with management to this point, I just, this is one I think you have to steer clear of. Just as we don't want to paint all specs with the same

brush, we don't want to paint all 8Ks with the same brush. But if you're filing an 8K to basically say, the president of our company misspoke? That's a problem. For the kids at home, this is not how to run a public company. Our email address is Radio at Fool.com. I got an email from Mike in Ohio who writes, I know the Motley Fool is typically more growth focused, but as I get older, I'm starting to think about rotating into some value stocks. How do I spot a value trap? I've heard this term a lot, but I'm still a bit fuzzy on this subject. Do you have some general rules of thumb to look out for to ensure that you don't get stuck in a value trap. What do you think, Ron?

Love the question. Right up my alley. Let's start with the definition of value trap first. In my opinion, it's an investment you make because you think the stock is undervalued. And that investment either doesn't make you the return you expected or you actually lose money. So in my experience, in most cases, a value trap arises because you bought a stock of a company that was having trouble. It was theoretically cheaper as a result, and you expect things to turn around.

It's when things don't turn around that a value investment becomes a value trap. And you keep holding on, hoping things will turn, believing things will turn, and it just keeps getting worse and worse and eventually leading to what we call a permanent loss of capital. You lose money. The easiest way to avoid most value traps is to only buy strong companies that are executing. well versus troubled companies that look cheap that you think will rebound. Now, that certainly is a strategy employed by value investors around the globe, including myself in a former career, but you've got to be really careful that you're picking companies that are temporarily impaired rather than permanently impaired. And that's not the easiest thing to do when researching

and analyzing a company. You're going to get it wrong a fair amount of times. That's going to lead to that permanent loss of capital, which will impact your returns in a severe way. And even in the worst of cases, could lead to you owning some companies that end up filing bankruptcy. I've had a couple of those, to be honest, and that really will kill your returns. So buy strong companies. Don't worry about turnarounds or companies that are failing, and you'll be able to avoid value traps. Well, and I'll just try and read Mike's mind a little bit with this question. It seems like at least part of what's underlying it is, he's moving out of growth mode as an investor and more into protect your wealth mode.

And it would seem as though some of the companies that we typically describe as blue chip stocks like Johnson and Johnson might be a better fit than, oh, I'm looking for something that's cheap. Yes, because value investments that are troubled and look cheap are actually sometimes more risky than you would ever think. They're not really what we think of as mature, stable companies. Look at the S&P 500 dividend aristocrats, look at the blue chip stocks out there that have very, very long track records of putting up great results. They're not going to knock the cover off the ball, but you're not taking on that risk, so you shouldn't expect them to knock the cover off the ball. They'll just earn you nice rates of return year after year after year with less risk.

Jason Moser, Ron Gross guys. We'll see you later in the show. Up next, a closer look at the healthcare sector with industry veteran Keith Spites. Stay right here. You're listening to Motley Fool Money. Welcome back to Motley Fool Money. I'm Chris Hill. Recently on this show, we've talked a lot about the great reopening here in the United States. But let's face it, the Great Reopening does not happen without COVID vaccines from Pfizer, Moderna, and Johnson, and Johnson. Here to talk about that. And more is Keith Spites. He's a healthcare technology consultant. For the past decade, he's been a contributing writer at the Motley Fool,

focusing on what else, the healthcare industry. Keith, thanks for being here. Good to be here, Chris. Let's start with the vaccine. I want to go a big picture to start. Where are we now, as you look at these three businesses, the vaccine distribution across the United States and around the world? Yeah, so Chris, I mean, the news in the United States is awesome. We're in a great position, Thanks to the vaccines that you've mentioned, Pfizer, Moderna, Johnson & Johnson, they've really helped the United States largely, not completely, but largely turn the corner in the fight against COVID-19. You know, you mentioned the reopening of the economy.

That's what we're seeing right now. We're seeing vaccines make the difference. I saw AMC Entertainment CEO, you know, AMC is one of the big meme stocks right now. AMC CEO was saying he watches every day, watches to see what's going on with vaccine news, because vaccines are the key, certainly for his company, but for a lot of other companies, you know, throughout the U.S. and the world. So here at home, you know, things are really going exceptionally well. But in other parts of the world, the news isn't so great. And especially in countries like India, it's just, you know, they really are facing some really serious challenges

with COVID-19. So when this started to break, sort of this cascade, a number of announcements from these three companies. For a good stretch of time there, they were essentially grouped together. Over the past, let's call it six weeks or so, it really seems to be that Johnson and Johnson has sort of broken off from the other two. And now you hear a lot of talk about Moderna's vaccine and Pfizer's vaccine in the same breath. Johnson and Johnson, they hit the pause button. How significant is it? How significant is it? is that in terms of vaccine distribution, and how significant is it for Johnson and Johnson as a company? Yeah, I think there are two answers there, Chris. In terms of how significant is it for vaccine

distribution, it does make a big difference because, you know, the U.S. was hoping to be able to be able to distribute 100 million J&J's vaccines. And Johnson and Johnson, really not through any fault of its own. It was really a contractor that had some serious manufacturing issues that have really caused the problems for Johnson & Johnson. And as a result, I think the latest numbers that I've seen, only about 5% of vaccines given to Americans were Johnson and Johnson's vaccine. That's remarkably low, considering it's the only single-dose vaccine that's one authorization. And you know, you would think, well, you know, a lot of people would really be attracted to that, that convenience, but those issues have caused that rate to be exceptionally low. But now, in terms of the question

of how does this impact Johnson Johnson, the real answer there is not very much. First of all, Johnson Johnson is selling this vaccine at cost during the pandemic. So it's making some revenue, but no profits. And so it's not impacting J&J's bottom line at all with some of the problems. that it's faced. The other thing is, Johnson & Johnson is the biggest healthcare company on the planet. And any one product just isn't going to move the needle tremendously for Johnson and Johnson. I mean, I think J&J has over 200 separate companies that is part of the J&J empire. And so the vaccine, you know, had it been as successful as anticipated, you know, would have been great for Johnson and Johnson, at least on the top line. But it's still just a small, small part of this company's business.

Last question, and then we'll move off of COVID-19. You look at shares of Johnson and Johnson and Pfizer, for that matter. They're up about 25 percent or so over the past year. Everything you said about Johnson and Johnson, the size of the company, no one thing is going to move the lever for that business and therefore for that stock. But I am curious if on the flip side, you are surprised at the fact that shares of Moderna have more than tripled over the past year. Or do you look at that and say, you know what?

It's a much smaller business. That makes sense to me. Yeah. Actually, it does make sense to me. I think that smaller companies, smaller stocks in general, not just in the healthcare space in any industry, smaller stocks are going to move more on good news. And that's what we've seen with Moderna particularly. We've also seen it with other companies that are on the horizon. Novavax, for example,

it was a huge, huge winner in 2020, particularly. A company like Pfizer, I would have expected Pfizer stock to move more than it has. I still personally view Pfizer is a little underappreciated because of the contributions that it's made. But again, Pfizer like Johnson Johnson has a lot of other products and a lot of other dynamics that come into play when you look at its stock movement. And I think investors are looking at some of the challenges that Pfizer faces and could face several years from now with some of its top drugs losing patent exclusivity. And so I think they're factoring all that in. But I think Pfizer is a stock that probably could have moved more than it has so far. All right.

Let's move off of this and talk about treatment for another health challenge, and that is Alzheimer's. Shares of biogen are up 40% in the month of June because the FDA approvals. approved Biogen's drug to treat Alzheimer's. This is the first medication aimed at slowing cognitive decline for people with Alzheimer's that regulators have approved. And yet it is not without controversy. Three members of the FDA advisory panel resigned over the decision. There are a couple of threads to get to here, but I guess my first question is, what is going on here? Was this a mistake to greenlight this treatment? Well, Chris, I call this nearly a biotech soap opera.

You could even bring in Greek mythology here. First of all, Biogen's drug is like the mythical phoenix. It literally rose from the ashes. I mean, this was a drug that not all that long ago had been relegated to the trash heap after seemingly failing late-stage clinical studies. Biogen later came back and did some further analysis, and they said, hey, you know, we actually see that there's a potential here. And they pursued that and then ultimately did file for FDA approval and ultimately won. But you're right, it's extremely, extremely controversial. The FDA's advisory committee that was convened to review the data came back and voted 10,

against recommending approval, one abstention. No member of that committee voted in favor of this drug being approved. They thought that another clinical study needed to be conducted to establish that the drug was actually effective. And so, and not even just that, several members of the committee wrote op-eds publicly urging the FDA not to go ahead and approve this drug. and the FDA did it anyway. So it's extremely controversial. I mean, where does this go from here? Because part of me, here's what you're saying and thinks, if those people are right, if this doesn't deserve approval, then it's essentially setting up patients and their families for huge disappointments.

It very well could. And I think that's the sad thing about this, Chris. I personally had a grandparent who had Alzheimer's disease before she passed. away. And, you know, we really need an effective treatment. And it would be a shame if, as some of the experts believe, this drug really doesn't work. Now, I hope it does. I hope, you know, biogen does have to conduct another clinical study. That was part of the accelerated approval decision. And so I hope it comes out and this drug actually does work. But if you look at the data, it's really a toss of the coin, I think, as to whether or not it's actually effective or not. In terms of timing, is the next trial biogen is going to be doing? Is that later this year?

Is this sometime in 2022? The confirmatory study will take years to conduct. It's likely that we won't know the results of that study, possibly eight or nine years from now. Well, let's close on a much more short-term note here. Look, this is an industry. you follow every single day. It's an industry I have only passing familiarity with. What are a couple of things that you think are going to be worth watching in the healthcare industry in the second half of 2021? Yeah, Chris, I think the biggest story by far will be coronavirus variants. What happens? You know, you've got, we already had the UK variant. We've got the Brazilian variant, but the really concerning one right now is the Delta variant that was identified in India.

And, you know, it just remains to be seen what's going to happen there. You know, how effective will our current vaccines be against these variants? And there could be more variants emerge as well. How effective will they be? Will we need booster doses more, you know, sooner rather than later to provide additional protection against variants? How effective will some, um, modified vaccines that both Pfizer and Moderna are working on targeting specific variants to be. They're conducting clinical studies. This is a huge study, a huge story because it doesn't just impact the healthcare world. It impacts the entire world. We've talked earlier about the economy reopening. If, you know, if they're really bad, dangerous variants emerge that vaccines

aren't as effective against, that could change the dynamics of the global economy. You can read his articles on fool.com. You can follow him on Twitter. The guy knows his stuff. So if you want to know health care, you need to be following Keith Spites. Keith. Thanks so much for being here. Thanks, Chris. Good to be with you. Up next. Ron Gross and Jason Moser return with two stocks on their radar and one correction from last week's show. Stay right here. You're listening to Motley Fool money. As always, people on the program may have interest in the stocks they talk about and the Motley Fool may have formal recommendations for or against. So, don't buy ourselves stocks based solely on what you're here.

Welcome back to Motley Full Money, Chris Hill here once again with Jason Moser and Ron Gross. Guys, on last week's show, we talked about the latest quarterly results from Casey's General Stores, as well as the acquisition of another convenience store chain that they had made. And we got several email from alert listeners, starting with James Brown in Nevada, who writes, in your discussion of Casey's General Stores, You mentioned that they had acquired Buckeys for $580 million, and that they were, quote, big in Texas. In truth, Casey's acquired Buckees from Nebraska, not the Buckees from Texas. An acquisition of Buckees from Texas would have been in the multi-billion dollar range

and would have come at the consternation of many a sad Texan. So that's on me because, Ron, when you did mention the Buckees acquisition, I didn't realize that there's a Buckees based in Nebraska. It's a division of Buchanan Energy. I confused it with Buckees, the one based in Texas, which is where almost all of their locations are. And I blame the Buckees in Texas, and here's why. Because we've talked about Cisco systems, the networking company, and Cisco, the wholesale food service distribution company. And they've got names that sound exactly the same, but they're in completely different industries. The Buckees in Nebraska, came first. It was established first. I feel like the one in Texas should have picked a different

name. That's fair. But thanks to James and others for pointing us. We make mistakes from time to time, and we're here to own up to them. Absolutely. We are nothing, if not accountable. Keep us accountable. Drop us an email, Radio at fool.com. Next week, El Pollo Loco is trying out its newest innovation drone delivery. The chicken restaurant chain will be testing what it calls door to backyard drone delivery with 10 of its locations in Southern California. Jason, they say this could reduce delivery costs by up to 30%. When you think about their concentration in California, that is not an insignificant sum of money they could be saving.

I absolutely believe it could save those costs. As a consumer, I would jump all over this just to try it, just to witness what happens. I mean, it would just be fascinating. I've got this itch to go trademark. Now, my Spanish is a little rusty, Chris, but I have an itch to go trademark El Pollo Volador, the flying chicken, because I feel like, you know, hey, that's where we're headed. You know, Kroger, which we discussed earlier today, has their own drone delivery pilot that's going on with a different company.

So here we go. It's starting. We're going to see how this works out. I'm a little skeptical. I am as well, but the fact that you've got all these tests going on, and I'm a little going on, it makes me think that five, 10 years from now, some of these businesses are going to make this work. And again, if any of the dozens of listeners in the Southern California area want to do some boots on the ground research, hit up their local El Pollo loco for some

drone delivery, let us know how it goes, because I am fascinated to see how this test goes for them. I'd love to see some video. The thing that I noted in that piece, I still can't quite figure out why this is how it works. But they talk about lowering your meal down from 80 feet on a wire. I mean, that's where I started thinking, hmm, maybe you could make that process a little because I envision the drone just touching down in your backyard and letting go and then take it back off.

It does feel like that 80 foot wire might add to the degree of difficulty. Let's go to our man behind the glass. Dan Boyd, before we get to the stocks on our radar, if you were living in Southern California, you'd give this a shot, wouldn't you just to see the drone coming by your backyard? Chris, I would give it a shot in the sense that I would take a gun and shoot the drones down and then go get people's food and eat it for myself. That's hostile. Wow.

Wow. We always appreciate how straightforward Dan is. All right, let's get the stocks on our radar. Jason Mosey, you're up first. What are you looking at this week? Yeah, taking a look at Corvo, ticker QRVO. It's a company in the radio frequency and semiconductor space, and they provide one of the industry's broadest portfolios of products in that space. One thing I'm primarily interested in with Corvo is

its progress in ultra-wideband technology, UWB. It's a radio technology that moves large quantities of data over wide-ranging scale of frequency bands with very low power for short distances. So it delivers superior location, accuracy, security, latency as we talk about 5G. Ultimately, UWB gives our smartphone spatial awareness, right? It makes it so that smartphones know where the other smartphones are, basically. And as the internet of things rolls out and more things are connected, we need to know where all of these things are. We need that spatial awareness. So with Corvo, I mean, they are pursuing that market. It's forecast to hit $2 billion by 2022, $2.7 billion by 2025. Dan, question about Corvo? Yeah, sure, Chris. So, Jason, you know, we keep hearing about the

semiconductor shortage out there right now. Corvo is a company that in March of 2020 in the beginning of the pandemic fell to the rest of the market, but since then has been on quite the tear. How are they avoiding all the semiconductor problems that other companies are seeing right now? Well, they are a beneficiary of a large relationship with a little company called Apple. And for better or worse, they have about a third of their revenue tied to Apple right now. And that's a good thing right now, because Apple continues to innovate. They're pushing out some really clever new devices, particularly the new phones. So I think as long as they're able to maintain that relationship with Apple, they should be given

a little bit of a benefit of the doubt, so to speak. Ron Gross, what are you looking at this week? I'm looking at GAN Limited, GAN, Small Cap Stock, recent recommendation at the Motley Fool. They build and operate online casino and sports betting sites for customers. They're a toll booth company. They take a small cut of every dollar wagered on their customer sites, customer like win resorts or non-casino companies like Churchill Downs. and FanDuel. They also offer simulated gaming for casino and gaming customers. Penn National

Gaming is a large customer in that segment. This looks interesting to me. Online betting is really starting to take off a growing industry. It was accelerated by the pandemic. I don't know a ton about the evolving gaming laws, so I need to dig into that a bit. Also, FanDual is a major percentage of revenue here, so there's a risk that I need to dig in with that as well. Dan? Question about GAN Limited? You know what, Chris, I don't have a question, but I do have a gripe. I don't watch a lot of TV, but I do watch live sports, right? And it used to be that every other commercial was an insurance company commercial.

Those companies have way too much money. But now, now every other commercial is a sports book commercial. These companies have way too much money. They're spending way too much time putting commercials on my baseball games. Which stock do you want to bet on here, Dan? Normally I like stocks that rhyme with my name, Chris, but not that. This one. Not this one. No, I'm going to go with Corvo. Nice. I love it. Sound logic. Sound logic. Jason Moser. Guys, thanks so much for being here. Thanks, Chris.

That's going to do it for this week's edition of Motley Fool Money. Show is Mixed by Dan Boyd. Our producer is Mac Rear. I'm Chris Hill. Thanks for listening. We'll see you next week.